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Abstract
Intermittent administration of parathyroid hormone (PTH) dramatically increases bone mass and currently is one of the most
effective treatments for osteoporosis. However, the detailed mechanisms are still largely unknown. Here we demonstrate
that conditioned media from PTH-treated osteoblastic and osteocytic cells contain soluble chemotactic factors for bone
marrow mesenchymal progenitors, which express a low amount of PTH receptor (PTH1R) and do not respond to PTH
stimulation by increasing cAMP production or migrating toward PTH alone. Conditioned media from PTH-treated
osteoblasts elevated phosphorylated Akt and p38MAPK amounts in mesenchymal progenitors and inhibition of these
pathways blocked the migration of these progenitors toward conditioned media. Our previous and current studies revealed
that PTH stimulates the expression of amphiregulin, an epidermal growth factor (EGF)-like ligand that signals through the
EGF receptor (EGFR), in both osteoblasts and osteocytes. Interestingly, conditioned media from PTH-treated osteoblasts
increased EGFR phosphorylation in mesenchymal progenitors. Using several different approaches, including inhibitor,
neutralizing antibody, and siRNA, we demonstrate that PTH increases the release of amphiregulin from osteoblastic cells,
which acts on the EGFRs expressed on mesenchymal progenitors to stimulate the Akt and p38MAPK pathways and
subsequently promote their migration in vitro. Furthermore, inactivation of EGFR signaling specifically in osteoprogenitors/
osteoblasts attenuated the anabolic actions of PTH on bone formation. Taken together, these results suggest a novel
mechanism for the therapeutic effect of PTH on osteoporosis and an important role of EGFR signaling in mediating PTH’s
anabolic actions on bone.
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Introduction
Osteoporosis is a major public health threat for more than 28
million Americans, affecting mostly postmenopausal women and
the elderly. It is a chronic bone disease mainly caused by an
imbalance in bone formation by osteoblasts and bone resorption
by osteoclasts. While continuous administration of parathyroid
hormone (PTH) causes bone loss, current interest in PTH focuses
on its ability to strongly augment bone mass in severe osteoporosis
patients by intermittent administration [1,2]. Indeed, Teripara-
tide, a recombinant form of human PTH 1–34, is the only FDA-
approved anabolic treatment for osteoporosis that functions by
stimulating bone formation in contrast to most other osteoporosis
drugs that suppress bone resorption.
The intact form of PTH is an 84-amino acid polypeptide
secreted from the parathyroid glands in response to changes in
serum calcium levels. In bone, PTH acts directly on cells of
osteoblast lineage (mainly osteoblasts and osteocytes) and indirect-
ly on osteoclasts because only osteoblasts express PTH type I
receptor (PTH1R) [3,4], a transmembrane G-protein coupled
receptor. Binding of PTH or PTH-related peptide (PTHrP) to
PTH1R activates two well-defined intracellular signal transduction
pathways: the protein kinase A (PKA) pathway, in which Gas
stimulates production of cAMP and activation of PKA, and the
protein kinase C (PKC) pathway where Gaq activates phospho-
lipase Cb with subsequent formation of diacylglycerol, PKC
activation and formation of 1,4,5-inositol trisphosphate. In
osteoblasts, PTH regulates most of its target proteins through
the PKA pathway (reviewed in [5]). Previous investigations have
identified a number of PTH-responsive genes in osteoblasts. Our
microarray studies revealed 125 PTH-regulated genes in osteo-
blastic UMR 106-01 cells [6] and more than 300 PTH-regulated
genes in the rat femoral osteoblast-rich secondary spongiosa after
PTH injections [7].
Extensive investigations have been performed to understand the
cellular mechanisms by which intermittent injection of PTH
increases osteoblast numbers. It has been concluded that, multiple
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7mechanisms, including activating bone lining cells, stimulating
osteoblast differentiation from osteoprogenitors, and preventing
osteoblast and osteocyte apoptosis, contribute to the anabolic
action of PTH [5,8]. However, whether PTH regulates the bone
marrow mesenchymal progenitors, including mesenchymal stem
cells, the multipotent progenitors for osteoblasts, chondrocytes and
adipocytes, and more committed osteoprogenitors, is not clear.
Several studies have investigated the effects of PTH on these cells
by assessing the number of colony forming unit-fibroblasts (CFU-
Fs) and results from these studies have been conflicting. Some
reports showed that PTH injection has no effect on CFU-F
number derived from bone marrow [9,10], while others suggest
that the hormone increases CFU-Fs, especially the number of
alkaline phosphatase-positive CFU-F colonies [11,12,13]. A
decrease in CFU-F number was also observed in mice after a
single injection of PTH, which was explained by the PTH-induced
adherence of mesenchymal progenitors to the bone surface [14].
Due to their self-renewal and differentiation abilities, mesen-
chymal progenitors hold great promise for tissue regeneration and
gene therapy. Injected progenitors migrate specifically to sites of
injury, inflammation, and tumor growth. Hence, the migratory
behavior of mesenchymal progenitors has been extensively
documented, but the signals guiding this migration and the
pathways regulating it are still largely unknown. Mesenchymal
stem cells may reside within a perivascular niche in the bone
marrow (reviewed in [15,16,17]) and osteoprogenitors are in the
bone marrow. Therefore, to become osteoblasts, they must
migrate away from their bone marrow location toward the bone
surface. Recent studies from Cao’s group found that PTH
stimulates the migration of these cells to the bone surface through
the release of the chemotactic factor TGFb1 from the bone matrix
[18].
We hypothesize that PTH can also directly stimulate the release
of chemotactic factors for mesenchymal progenitors from mature
osteoblasts. Indeed, we demonstrate that PTH stimulates osteo-
blasts and osteocytes to release potent chemotactic factor(s) for
mesenchymal progenitors in vitro. Using a number of approaches,
including inhibitor, neutralizing antibody, and siRNA, we
identified this chemotactic factor as amphiregulin, which acts on
the epidermal growth factor receptor (EGFR) in mesenchymal
progenitors to promote their migration in vitro. EGFR is a
tyrosine kinase receptor that, upon ligand binding, activates
several important intracellular signal transduction pathways such
as Ras-Raf-MAP-kinase and PI-3-kinase-Akt and modulates a
variety of cell functions such as proliferation, survival, adhesion,
migration and differentiation [19]. Recent studies demonstrate
that this signaling pathway plays an important role in bone
metabolism (reviewed in [20]). Here, we demonstrate that, in vivo,
the loss of EGFR activity specifically in osteoprogenitors/
osteoblasts inhibited PTH’s stimulatory action on bone formation.
Overall, our findings suggest an important role of the EGFR
signaling pathway in regulating the anabolic response to PTH.
Materials and Methods
Chemicals and Reagents
Rat PTH(1–34) was purchased from Bachem whereas human
PTH(1–34) was synthesized by the MGH Peptide Core Facility.
Recombinant human EGF, TGFa, HB-EGF, and amphiregulin
were purchased from R&D Systems. SB202190, wortmannin,
U0126, GM6001, and PD153035 were obtained from Calbio-
chem. Gefitinib was a product of LC Laboratories.
Isolation and culture of human and rat bone marrow
mesenchymal progenitors
Human bone marrow aspirates were purchased from Allcells
and purified through Ficoll gradient (GE Healthcare) to obtain
bone marrow mononuclear cells. These cells were seeded and
grown in a minimal essential medium (aMEM) supplemented with
20% fetal bovine serum (FBS), 2 mM L-glutamine, and 100 mM
L-ascorbate-2-phosphate for about 2 weeks to establish the
adherent culture. To obtain rat mesenchymal progenitors,
Sprague-Dawley rats at 1-month-old (Charles River) were
euthanized by CO2 inhalation and the bilateral femora and tibiae
were dissected under sterile conditions and washed in aMEM.
Bone marrow cells were collected by flushing media through
bones, filtered through a 70-mm cell strainer, and cultured in
aMEM containing 10% FBS. Only passages less than five were
used in the experiments. The human and rat mesenchymal
progenitors had a fibroblast-like morphology in culture, were
homogeneously CD90
+CD105
+CD146
+CD45
2 (human) and
CD90
+CD49e
+CD45
2CD34
2 (rat) (data not shown). All animal
work performed in this report was approved by the Institutional
Animal Care and Use Committee (IACUC) at the University of
Pennsylvania and Massachusetts General Hospital.
Collection of conditioned media
UMR 106-01 cells were maintained in MEM with 5% FBS. Rat
primary calvarial osteoblastic cells were obtained from neonatal
calvariae by sequential digestions with collagenase and trypsin as
described previously [21] and cultured in MEM containing 10%
FBS until confluence. Then the media was switched to osteoblast
differentiation media (BGJb medium containing 10% FBS,
10 mM b-glycerophosphate, and 50 mg/ml ascorbic acid) for 1
week. MC3T3-E1 cells were maintained in aMEM with 10%
FBS. After confluence, cells were cultured in osteoblast differen-
tiation media (aMEM with 10% FBS and 50 mg/ml ascorbic acid)
for 4 days. All above cultures were incubated at 37uCi na
humidified atmosphere containing 5% CO2. The osteocytic cells
Ocy491 were isolated from long bones of 8 kb DMP1-GFP
transgenic mice expressing green fluorescent protein (GFP)
specifically in osteocytes and carrying an immortalizing antigen
(tsAgSV40). Briefly, long bones (femora and tibiae) of 4-weeks old
double transgenic (8 kb DMP1-GFP;tsAgSV40) mice were
dissected under sterile condition and cells were isolated by
sequential collagenase and EDTA digestions followed by FACS
sorting for GFP-positive cells. GFP-positive sorted cells displayed
the dendritic and stellate morphology characteristic of an
osteocytic population. They were maintained in aMEM with
10% FBS at 33uC for proliferation and switched to 37uCt o
inactivate tsAg expression at confluence. After 2 weeks in culture
at non permissive condition, Ocy491 cells express high levels of
osteocytic markers SOST, E11 and DMP1 and a very low level of
osteoblastic marker Kera compared to primary osteoblastic cells,
as assessed by qRT-PCR (data not shown). According to this
pattern of gene expression and, as previously described, Ocy491
can be classified as young osteocytes [22].
To collect conditioned media, cells were washed once with
aMEM and then maintained in serum-free aMEM overnight
followed by PTH treatment (10 nM human PTH(1–34) for
Ocy491 cells and 10 nM rat PTH(1–34) for all other cells unless
otherwise stated). Conditioned media were then harvested 4 hrs
after addition of PTH and centrifuged at 3000 rpm for 10 min at
4uC to remove cell debris before storage at 280uC. Conditioned
media collected from vehicle-treated cells were used as control.
PTH Stimulates the Migration of Bone Progenitors
PLOS ONE | www.plosone.org 2 December 2012 | Volume 7 | Issue 12 | e50099Chemotaxis assay
To measure the migration of total bone marrow cells, rat bone
marrow cells flushed from long bones were washed with aMEM
once and then plated (8610
6 total bone marrow cells/well) in the
upper chamber of Costar 6-well transwell plates with 3-mm pore
polycarbonate membranes (Corning, NY). Conditioned media
were loaded in the bottom wells. After incubating plates at 37uCi n
humidified 5% CO2 for 24 hrs, the cells in the upper chamber
were removed by washing with phosphate-buffered saline (PBS)
followed by cotton scrubbing. The migrated cells were collected
from the bottom part of the membrane by trypsinization and from
medium in the lower wells and then counted using a hemocy-
tometer.
The chemotactic activity of conditioned media for mesenchymal
progenitors was evaluated using a 96-well microchemotaxis
Boyden chamber (Neuro Probe). Mesenchymal progenitors were
lifted by trypsin, washed once in aMEM and resuspended in
aMEM. Cells (5000 cells/25 ml) were added to the upper wells and
conditioned media harvested from osteoblastic and osteocytic cells
were added to the lower wells. The contents of the upper and
lower wells were separated by a filter with 8-mm pores. The
chamber was then incubated at 37uC in humidified 5% CO2 for
5 hr. After incubation, cells on the upper side of the filter were
mechanically removed using soft paper. The migrated cells on the
lower side were fixed and stained with 0.3% crystal violet in
methanol. Under a microscope, a total of five fields per filter were
counted to calculate the average cell number per field. The
chemotactic index is defined by setting the number of migrated
cells toward control conditioned medium or aMEM as 1. To test
the effects of individual signaling pathways on the migration,
mesenchymal progenitors were mixed with inhibitor or neutral-
izing antibody first and then immediately loaded into the upper
wells for the chemotaxis assay.
cAMP assay
UMR 106-01, human and rat mesenchymal progenitors were
seeded in 60-mm dishes and treated with 10 nM rat PTH(1–34)
for 15 min. Cell lysates were then harvested to measure cAMP
contents normalized against total protein amounts using a
Parameter Cyclic AMP Assay kit (R&D Systems).
Immunoblotting
Whole cell extracts of mesenchymal progenitors were separated
by SDS-PAGE and immunoblotted as previously described [23]
with antibodies raised against total EGFR (Santa Cruz # sc-03),
the phosphorylated form of EGFR (Cell Signaling # 3777), total
Akt (Cell Signaling #9272), the phosphorylated form of Akt (Cell
Signaling # 4051), total p38MAPK (Cell Signaling # 9212), the
phosphorylated form of p38MAPK (Cell Signaling # 4511), and
b-actin (Santa Cruz # sc-47778). Secondary antibodies were
purchased from Santa Cruz (goat anti-mouse # sc-2005 and goat
anti-rabbit # sc-2004).
Flow cytometry analysis
To detect the EGFR surface expression, ficoll gradient-purified
human bone marrow cells or cultured mesenchymal progenitors
were washed with PBS and resuspended in PBS containing 2%
FBS. The cells were then incubated with PE-conjugated antibody
for EGFR (BD Biosciences) for 45 min on ice. They were washed
with PBS and analyzed by a flow cytometer (Beckman Coulter).
Radiolabeled EGF ligand binding and calculation of EGFR
number in mesenchymal progenitors
Human mesenchymal progenitors were seeded in 24-well plates
overnight. On the next day, cells were washed twice with PBS and
incubated with aMEM containing 1 mg/ml BSA and a series of
concentrations of mouse
125I-EGF (GE Healthcare) for 2 hr at
37uC. After washing twice with PBS, cells were lysed in 0.5 M
NaOH and the amount of radioactivity was counted in a gamma
counter (1282 CompuGamma CS, LKB Wallac). Nonspecific
binding was calculated as the radioactivity remaining bound to the
cells in the presence of 250-fold cold EGF. Cell numbers were
counted in a hemocytometer after they had been harvested from
separate replicate plates. To calculate the number of EGFR on
mesenchymal progenitors and the Kd value, a saturation curve
was generated and analyzed using nonlinear regression (Graph-
pad, Prism5).
siRNA knockdown of EGFR and amphiregulin
DsiRNA TriFECTa Kits (IDT), including
HSC.RNAI.N005228.12 for human EGFR and
HSC.RNAI.N017123.12 for rat amphiregulin, were used to
knockdown the EGFR expression in human mesenchymal
progenitors and amphiregulin expression in UMR 106-01 cells,
respectively, according to the manufacturer’s protocol. Two to
three days later, cells were harvested for RNA, protein lysates, or
migration assay.
RNA isolation and qRT-PCR
Total RNA was isolated from cells using Tri Reagent (Sigma-
Aldrich). A TaqmanH Reverse Transcription kit (Applied Biosys-
tems) was used to reverse transcribe mRNA into cDNA. Following
this, qPCR was performed using a Power SYBRH Green PCR
Master Mix kit (Applied Biosystems). Primer sequences are listed
in Supplemental Table S1.
Skeletal characterization and PTH anabolic treatment in
osteoprogenitor/osteoblast-specific EGFR deficient mice
Col-Cre Egfr
Wa5/flox mice and their controls were generated as
described previously [24]. Briefly, we bred Col 3.6-Cre with
Egfr
Wa5/+ to obtain Col-Cre Egfr
Wa5/+. These mice were then
crossed with Egfr
flox/flox to generate Col-Cre Egfr
Wa5/flox mice and
their Wa5 (Egfr
Wa5/flox) and wild-type (Col-Cre Egfr
flox/+ and
Egfr
flox/+) littermates. Four-month-old mice were injected daily
with either vehicle (saline) or PTH (100 mg/kg/day) for 5 weeks (5
days per week). There was no significant difference in body weight
among genotype groups and between treatments. One day after
the last injection, both tibiae were harvested, one for peripheral
quantitative computed tomography (pQCT) analysis using an
XCT Research SA (Stratec Medizintechnik, Pforzheim, Germany)
followed by micro-computed tomography (microCT) measure-
ment using Skyscan 1172 high resolution microCT (Skyscan,
Belgium), and another one for bone histomorphometry. The
experimental details were described previously [24].
Statistical analysis
All results are expressed as means 6 SEM of triplicate
measurements with all experiments being repeated independently
at least three times. Unpaired Student’s t test was used to evaluate
the statistical difference between two groups. In cases of multiple
groups, differences were analyzed with one-way analysis of
variance (ANOVA) with Bonferroni post test. Values of p,0.05
were considered significant. Statistical analysis was performed with
GraphPad Prism5.
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Bone marrow mesenchymal progenitors migrate toward
PTH-stimulated osteoblasts and osteocytes
We initially performed migration assays using freshly harvested
rat bone marrow cells. We found that while a significant number
of bone marrow cells (26.7% of the cells plated in the upper
chamber) migrated toward aMEM, there were more cells (41.4%)
that migrated toward conditioned media collected from UMR
106-01, a rat osteoblastic cell line (Fig. 1A). However, we did not
observe any further increase in the number of migrated cells when
conditioned media from PTH-treated UMR 106-01 cells were
tested (Fig. 1A), suggesting that osteoblastic culture media contain
migration factor(s) for bone marrow cells.
Since bone marrow mesenchymal progenitors are a rare
subpopulation of the total bone marrow with an approximate
number of one in 10
5–10
6 bone marrow mononuclear cells [25],
we could not conclude based on the total bone marrow migration
results whether the conditioned media promoted the migration of
mesenchymal progenitors. To specifically observe the migration of
mesenchymal progenitors, we expanded these cells in culture and
then used them for the migration assay. As shown in Fig. 1B (left
panel) and C, very few rat mesenchymal progenitors migrated
toward aMEM alone whereas conditioned media from UMR 106-
01 cultures contained factor(s) that stimulated their migration
across the filter. Interestingly, conditioned media from PTH-
treated UMR 106-01 cells resulted in more than a 2-fold increase
in the number of migrated mesenchymal progenitors, suggesting
that PTH treatment increases the amount of migratory factor(s) for
mesenchymal progenitors in the conditioned media.
To confirm that this response is not limited to UMR 106-01
cells but is a general response of osteoblastic cells to PTH, we
tested two other osteoblastic cells: rat primary calvarial osteoblasts
and murine osteoblastic cells, MC3T3-E1. These cells start as
osteoprogenitors and have the ability to undergo osteoblastic
differentiation in vitro. We collected conditioned media at the
differentiation stage with or without PTH treatment and used
them for the chemotaxis assay. Consistent with the above UMR
106-01 cell results, conditioned media from PTH-treated primary
osteoblasts and MC3T3-E1 cells led to a 3.2- and 1.6-fold
increase, respectively, in mesenchymal progenitor migration
compared to non-treated conditioned media (Fig. 1B). A similar
effect was observed with human mesenchymal progenitors
(Fig. 1B). Osteocytes are terminally differentiated osteoblasts
trapped in the bone matrix. They form an extensive connecting
network through which they are capable of controlling osteoblast
Figure 1. Conditioned media from PTH-treated osteoblastic cells contain chemotactic factors for bone marrow mesenchymal
progenitors. (A) Migration of freshly flushed rat bone marrow cells toward PTH and conditioned media from UMR 106-01 cells. Bone marrow cells
flushed from rat long bones were immediately seeded in the upper chamber of transwell plates. The bottom wells were loaded with media alone
(aMEM), media containing 10 nM PTH (PTH), or conditioned media (CM) collected from UMR106-01 cells that had been treated with control (CON) or
10 nM PTH (PTH) for 4 hr. The number of cells that migrated to the bottom wells was counted 24 hr later. aMEM containing 5% FBS (FBS) was used as
a positive control for cell migration. *: p,0.05; **: p,0.01 vs. aMEM. (B) Conditioned media from various PTH-treated osteoblastic and osteocytic cells
stimulated the migration of either human or rat mesenchymal progenitors (MP) in the Boyden chamber assay. The cells seeded in the upper wells are
depicted at the top and conditioned media loaded in the lower wells are shown at the bottom. M: aMEM. ***: p,0.001 vs. aMEM; &: p,0.01; #:
p,0.001 vs. CON. (C) Microscopic images of the mesenchymal progenitors that migrated to the lower sides of filters in the assay depicted in B. (D)
The migration of mesenchymal progenitors stimulated by conditioned media from PTH-treated osteoblasts is not chemokinesis. Mesenchymal
progenitors were suspended in conditioned media harvested from either control or PTH-treated UMR 106-01 cells and seeded in the upper chambers.
The lower wells were filled with conditioned media, resulting in a total of 4 combination types. **: p,0.01 vs. CON/CON. (E) Time course of the
release of chemotactic factor(s) from osteoblasts after PTH treatment. UMR 106-01 cells were treated with PTH and conditioned media were
harvested at indicated time points and loaded in the lower wells for chemotaxis assays. ***: p,0.001 vs. time 0 hr. (F) The dosage effects of PTH on
chemotactic factor(s) release from osteoblasts. UMR 106-01 cells were treated with different doses of PTH for 4 hr and then conditioned media were
harvested for chemotaxis assays. *: p,0.05; **: p=0.06; ***: p,0.001 vs. 0 nM.
doi:10.1371/journal.pone.0050099.g001
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found that conditioned media from PTH-treated osteocytic
Ocy491 cells also promoted the migration of mesenchymal
progenitors (2.8-fold, Fig. 1B right panel), suggesting that PTH
not only acts on mature osteoblasts but also on osteocytes to
stimulate the release of migratory factor(s) for mesenchymal
progenitors. In the following experiments, unless otherwise stated,
similar results between rat and human mesenchymal progenitors
were observed.
To distinguish whether this phenomenon is chemotaxis
(concentration-dependent cell migration) or chemokinesis (random
cell motility), we suspended mesenchymal progenitors in condi-
tioned media from either control or PTH-treated UMR 106-01
cells and plated them in the upper wells. The lower wells were
filled with conditioned media from either control or PTH-treated
UMR 106-01 cells. Among all four possible combinations, the
number of migrated cells in the chambers with control conditioned
media in the upper well and PTH-treated conditioned media in
the lower well was the highest (Fig. 1D). This result indicates that
PTH-induced migratory factor(s) in osteoblast culture media are
chemoattractant(s) for mesenchymal progenitors.
Next, we examined the time course of the chemotactic factor
release from PTH-treated cells. As shown in Fig. 1E, the release of
chemoattractants seems to be a very rapid process since
conditioned media from cells treated with PTH as early as
30 min contained a high enough amount of factor(s) to signifi-
cantly increase the migration of mesenchymal progenitors. The
chemotactic activity of conditioned media continuously increased
up to 4 hr after PTH treatment. Dose response experiments
revealed that conditioned media from cells treated with as little as
0.1 nM PTH was able to significantly stimulate the chemotaxis of
mesenchymal progenitors, but the peak occurred around 10 nM
PTH (Fig. 1F). In summary, our data clearly demonstrate that
PTH stimulates osteoblastic and osteocytic cells to produce soluble
chemoattractants for bone marrow mesenchymal progenitors.
PTH itself is not a chemotactic factor for mesenchymal
progenitors
Since we did not remove PTH from the conditioned media
before the migration assay, it is possible that PTH might be a
direct chemotactic factor for mesenchymal progenitors. To
exclude this possibility, we first examined the PTH1R expression
in mesenchymal progenitors. Compared to osteoblastic UMR 106-
01 cells, rat mesenchymal progenitors only express 0.62% of
PTH1R mRNA as shown by qRT-PCR (Fig. 2A). In culture, rat
primary calvarial osteoblastic cells go through three stages:
proliferation (the first week), differentiation (the second week),
and mineralization (the third week). qRT-PCR demonstrated that
PTH1R expression was strongly elevated during this osteoblastic
differentiation process with more than a 34-fold increase at the
mineralization phase compared to the proliferation phase (Fig. 2B).
These results clearly indicate that PTH1R is expressed at a much
higher level in mature osteoblasts compared to mesenchymal
progenitors, which is consistent with previous reports [26,27]. The
major signaling pathway activated by PTH in osteoblasts is the
cAMP/PKA pathway. While it led to a 58-fold increase in cAMP
in UMR 106-01 cells, PTH treatment did not increase cAMP
production in mesenchymal progenitors (Fig. 2C), indicating that
mesenchymal progenitors do not have a detectable response to
PTH stimulation. Furthermore, we performed migration assays
adding only PTH to the bottom wells and found that it has no
chemotactic activity toward mesenchymal progenitors (Fig. 2D).
Meanwhile, there was a 3-fold increase in the number of cells that
migrated toward conditioned media from PTH-treated samples
compared to that toward control conditioned media, and this
number was comparable to that toward serum-containing medium
(Fig. 2D). Moreover, PTH itself did not enhance the migration of
total bone marrow cells (Fig. 1A). These data clearly indicate that
it is a PTH-induced downstream target, and not PTH itself, that
stimulates the chemotaxis of mesenchymal progenitors.
Blocking PI3K and p38MAPK activities in mesenchymal
progenitors abolishes their migration toward PTH-
treated osteoblasts
To identify the chemotactic factors released from PTH-
stimulated osteoblasts, we first used inhibitors to study which
intracellular signaling pathways in mesenchymal progenitors are
important for mediating their migration toward PTH-stimulated
osteoblasts. As shown in Fig. 3A, while inhibitors for MAPK
(U0126), PI3K (wortmannin), and p38MAPK (SB202190) had no
effect on the migration of mesenchymal progenitors toward
normal osteoblastic conditioned media, wortmannin and
SB202190, but not U0126, completely blocked the increase in
mesenchymal progenitor migration toward conditioned media
from PTH-treated osteoblasts, suggesting that PI3K/Akt and
p38MAPK pathways are both essential for the action of PTH-
released chemotactic factors from osteoblasts. Furthermore, we
collected the conditioned media from osteoblasts and added them
to the mesenchymal progenitor culture. Western blots showed
rapid and strong increases in both phosphorylated Akt and
p38MAPK amounts in mesenchymal progenitors after being
treated with conditioned media from PTH-treated osteoblastic
cells (Fig. 3B). However, PTH itself had no detectable effect on
these pathways within 15 min of treatment (Fig. 3C), providing
additional evidence that PTH does not directly act on mesenchy-
mal progenitors to promote their migration.
EGFR signaling in mesenchymal progenitors is critical for
their migration toward PTH-treated osteoblasts
We have previously shown that amphiregulin is an immediate-
early gene induced by PTH in osteoblasts [21]. Amphiregulin
belongs to a family of epidermal growth factor (EGF)-like ligands
which also includes EGF, transforming growth factor a (TGFa),
betacellulin, heparin-binding-EGF (HB-EGF) and epiregulin.
Since the receptor for these ligands, EGFR, plays a critical role
in cancer cell migration and tumor metastasis [28], we investigated
whether EGFR signaling in the mesenchymal progenitors
mediates the chemotactic effects of conditioned media from
PTH-treated osteoblasts.
Although the EGFR is critical for the mobilization of
hematopoietic stem cells [29], we found no detectable amount of
cell surface EGFR on freshly flushed bone marrow cells (Fig. 4A),
suggesting that the majority of hematopoietic lineage cells lack the
expression of EGFR. However, after culture, the plastic adherent
bone marrow mesenchymal progenitors are EGFR-positive cells
(Fig. 4A), which is consistent with previous reports that EGF-like
ligands regulate mesenchymal progenitor proliferation, differenti-
ation, and apoptosis [30,31]. The quantitative expression level of
EGFR in mesenchymal progenitors has not been studied. We
performed receptor-ligand binding assays using
125I-labeled EGF
and subsequent nonlinear regression analyses which revealed a
single class of EGF binding sites on mesenchymal progenitors with
a dissociation constant of 34.9 pM and receptor number of
1.4610
4 per cell (Fig. 4B).
To determine if the activation of EGFR is important for PTH-
induced mesenchymal progenitor migration, cells were treated
with osteoblast conditioned media and EGFR phosphorylation
PTH Stimulates the Migration of Bone Progenitors
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media from PTH-treated osteoblasts had increased phosphorylat-
ed EGFR compared to control (Fig. 5A). Addition of an EGFR-
specific inhibitor, gefitinib, abolished the enhanced levels of
phosphorylated Akt and p38MAPK (Fig. 5B), suggesting that
activation of EGFR in mesenchymal progenitors is crucial for
promoting both PI3K/Akt and p38MAPK pathways. Moreover,
addition of the EGFR inhibitor PD153035 to both the upper and
lower wells of the Boyden chamber partially blocked the
chemotactic activity of PTH-treated conditioned media (Fig. 5C).
PD153035 alone had no effect on the cell migration toward
control conditioned media. Similarly, when they were pretreated
with an EGFR neutralizing antibody, the mesenchymal progen-
itors had decreased migration toward PTH-treated conditioned
media with a larger decrease observed by rat mesenchymal
progenitors than human mesenchymal progenitors (Fig. 5D).
Control IgG had little effect on this migration. Lastly, we used a
siRNA approach to decrease the expression of EGFR in
mesenchymal progenitors. Two siRNAs against different regions
of the human EGFR coding region were transfected separately
into mesenchymal progenitors. qRT-PCR and Western blots
showed that both of them efficiently knocked down the EGFR
expression at both mRNA and protein levels (more than 90%
decrease) (Fig. 5E and F). Subsequent chemotaxis assays revealed
that, while mock siRNA-transfected mesenchymal progenitors still
migrated more toward PTH-treated conditioned media, EGFR-
specific siRNA-transfected mesenchymal progenitors no longer
exhibited preference toward this media (Fig. 5G). Taken together,
our data clearly show that EGFR activity in mesenchymal
progenitors at least partially mediates their migration toward
PTH-treated osteoblasts.
Amphiregulin released from PTH-treated osteoblastic
cells recruit mesenchymal progenitors
To identify the ligands responsible for activation of EGFR in
mesenchymal progenitors, we performed chemotaxis assays with
four major EGF-like ligands (EGF, HB-EGF, TGFa and
amphiregulin) and found that all of them are potent chemotactic
factors for mesenchymal progenitors (Fig. 6A). Among them, HB-
EGF and TGFa have the strongest effects since the number of cells
that migrated toward 0.3 nM of these ligands was comparable to
that toward serum. EGF exhibited the least potent effect, but the
number of cells that migrated toward 0.3 nM EGF was still 7.6-
fold more than that toward media alone.
GM6001 is a general inhibitor for metalloproteinases including
MMP (matrix metalloproteinase), adam (a distintegrin and
metalloproteinase), and adamts (a disintegrin and metalloprotei-
nase with thrombospondin motif), which play important roles in
Figure 2. PTH itself is not a chemotactic factor for mesenchymal progenitors. (A) qRT-PCR quantification of mRNA levels of PTH1R in
UMR106-01 cells and rat mesenchymal progenitors in culture. ***: p,0.001 vs. UMR. (B) The expression of PTH1R in rat calvarial osteoblasts increases
dramatically during their osteogenic differentiation as measured by qRT-PCR. PRO: proliferation stage; DIF: differentiation stage; MIN: mineralization
stage. **: p,0.01; ***: p,0.001 vs. PRO. (C) PTH stimulates cAMP production in UMR 106-01 cells but not mesenchymal progenitors. ***: p,0.001 vs.
con. (D) PTH alone does not stimulate the migration of mesenchymal progenitors. Chemotaxis assays were performed with lower wells filled with
aMEM, aMEM containing 10 nM PTH, conditioned media from control- and PTH-treated UMR 106-01 cells, and aMEM containing 5% FBS. ***:
p,0.001 vs. CON.
doi:10.1371/journal.pone.0050099.g002
Figure 3. PI3K/Akt and p38MAPK pathways are required for the migration of mesenchymal progenitors toward conditioned media
from PTH-treated osteoblastic cells. (A) Chemotaxis assays were performed with mesenchymal progenitors and conditioned media from either
control- or PTH-treated UMR 106-01 cells in the presence or absence of pathway-specific inhibitors. D: DMSO; U: U0126 (20 mM); WT: wortmannin
(3 mM); SB: SB202190 (20 mM). Inhibitors were added to both upper and bottom chambers. ***: p,0.001 vs. CON CM D; #:p ,0.001 vs. PTH CM D. (B)
Conditioned media from PTH-treated UMR 106-01 cells stimulated the phosphorylation of Akt and p38MAPK in MSCs. (C) PTH alone did not activate
Akt and p38MAPK pathways in mesenchymal progenitors.
doi:10.1371/journal.pone.0050099.g003
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including all EGF-like ligands [32,33]. Interestingly, we found
that pretreatment of UMR 106-01 cells with GM6001 also
impaired the chemotactic activity of PTH-treated conditioned
media (Fig. 6B), implying that PTH-released osteoblastic chemo-
tactic factor(s) might originally exist in a membrane-bound form.
Our previous studies reveal that among all EGF-like ligands,
amphiregulin is the most up-regulated by PTH in osteoblasts [21].
Since the above mentioned migration assays (Fig. 1B) found that
PTH-treated osteocytes secreted more chemotactic factors for
mesenchymal progenitors compared to vehicle-treated cells, we
next examined whether PTH stimulates amphiregulin expression
in these cells. Indeed, qRT-PCR validated that amphiregulin
mRNA was highly stimulated by PTH in Ocy491 cells (29-fold) at
1 hr (Fig. 6C). To investigate the role of amphiregulin in this
PTH-induced mesenchymal progenitor migration, knockdown of
amphiregulin was performed by transfecting UMR 106-01 cells
with two different non-specific siRNAs or two siRNAs against
different regions of the amphiregulin coding sequence. qRT-PCR
revealed that amphiregulin-specific siRNAs inhibited PTH-
induced amphiregulin expression more than 60% (Fig. 6D).
Interestingly, conditioned media collected from these cells pre-
treated with PTH lost their chemotactic activity for mesenchymal
progenitors (Fig. 6E), suggesting that amphiregulin from osteo-
blastic cells and EGFR from mesenchymal progenitors constitute
the major signaling pathway mediating the PTH-induced migra-
tion of mesenchymal progenitors toward osteoblasts and osteo-
cytes. Consistent with these results, we also found that amphir-
egulin is able to strongly activate the PI3K/Akt and p38MAPK
pathways in mesenchymal progenitors (Fig. 6F).
Loss of EGFR activity in osteoprogenitors/osteoblasts
attenuates the anabolic response to PTH
The 3.6 kb alpha1(1) collagen promoter is activated early
during osteogenic differentiation and expressed in osteoprogeni-
tors [34]. As a result, Cre driven by this promoter targets
osteoprogenitors and osteoblasts [35] and has been used success-
fully to knock down preosteoblast/osteoblast expression in a
number of mouse models. Wa5 has a single missense mutation
Asp833Gly in the highly conserved DFG domain of the EGFR
kinase catalytic loop and codes for a kinase dead, dominant
negative receptor [36]. While Wa5 homozygous mice, similar to
Egfr null mice, are embryonic lethal, the heterozygous mice
(Egfr
Wa5/+) have significantly attenuated EGFR activity compared
to wild-type mice [36] but the remaining low activity of EGFR is
sufficient to maintain their viability and retain normal bone
[24,37]. We have previously demonstrated that, while the skeletal
phenotype of Col-Cre Egfr
flox/flox mice are indistinguishable from
wild-type mice due to the incomplete conversion of floxed alleles
by Cre, further inactivation of EGFR signaling by introducing the
Wa5 allele (Col-Cre Egfr
Wa5/flox mice) led to decreased EGFR
activity in osteoprogenitors and reduced total and trabecular bone
mineral density (BMD) at 3 and 7 months of age [24]. To
determine if the reduction of EGFR activity in osteoprogenitors
reduces the anabolic response to PTH, we treated Col-Cre Egfr
Wa5/
flox mice and their Wa5 and wide-type siblings with daily PTH
injections for 5 weeks. pQCT analyses of proximal tibiae showed
that PTH significantly increased total and trabecular BMDs in
wild-type and Wa5 mice but had no effects on BMDs of Col-Cre
Egfr
Wa5/flox mice (Fig. 7A). This finding is consistent with a previous
report that Egfr
Wa5/+ mice respond to PTH anabolic injections
normally [38] and therefore we excluded Egfr
Wa5/flox mice from
further analyses. MicroCT measurements confirmed that PTH
significantly increased bone volume/tissue volume fraction (BV/
TV, 38.0%) and trabecular number (TbN, 45.8%) in the tibial
trabecular bone and improved the structural integrity and
mechanical strength of the trabecular bone by decreasing the
trabecular pattern factor (TbPf, 63.5%) and surface model index
(SMI, 42.8%) in wild-type mice but had no significant effects on
these parameters in the Col-Cre Egfr
Wa5/flox mice (Fig. 7B).
Interestingly, bone histomorphometry revealed that PTH in-
creased osteoblast surface (40.5%) and osteoid surface (53.6%) in
wild-type mice but these effects were blunted in Col-Cre Egfr
Wa5/flox
mice (Fig. 7C), suggesting that PTH-induced osteoblast formation
is suppressed by the loss of EGFR in osteoprogenitors. Consistent
with our previous data [24], Col-Cre Egfr
Wa5/flox mice had
significantly decreased total and trabecular BMDs, BV/TV,
TbTh and osteoblast surface compared to wide-type (Fig. 7).
Discussion
It is well established that intermittent injections of PTH
stimulates both bone resorption and bone formation and leads
to a net increase in bone formation. However, its exact mechanism
of action, in particular its regulation of mesenchymal progenitors,
is not completely understood. We tested mesenchymal progenitors
from two sources (human and rat), osteoblasts from three sources
(UMR 106-01, MC3T3-E1, and primary osteoblasts), and an
Figure 4. Mesenchymal progenitors express EGFR. (A) Flow cytometry analyses demonstrate that cultured mesenchymal progenitors (MPs) but
not freshly isolated bone marrow mononuclear cells (BMMCs) express EGFR surface antigen. Blue curve: EGFR antibody; red curve: isotype control. (B)
Saturation curve of binding of
125I-EGF to mesenchymal progenitors.
doi:10.1371/journal.pone.0050099.g004
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on osteoblastic and osteocytic cells to rapidly stimulate the release
of chemotactic factors for mesenchymal progenitors in vitro. We
also demonstrated that the reduction of EGFR activity in
osteoprogenitors/osteoblasts in mice led to the inhibition of the
bone anabolic response to PTH. As summarized in Fig. 8, we
propose that PTH injection rapidly stimulates osteoblasts on the
bone surface and osteocytes inside the bone matrix to produce the
chemotactic EGF-like ligand, amphiregulin, which binds to the
EGFR on mesenchymal progenitors in the bone marrow,
promotes the activation of the PI3K/Akt and p38MAPK signaling
pathways in those cells, and activates their migration toward the
bone surface. We believe that this novel mechanism contributes to
part of PTH’s anabolic actions since multiple other mechanisms
have been previously proposed [5,8]. Our previous reports
demonstrated that amphiregulin is a potent mitogen for mesen-
chymal progenitors [21] and that it inhibits their differentiation
into mature osteoblasts [23], and therefore maintains these
progenitors in an undifferentiated state. Once at the bone surface,
these progenitors will then differentiate into mature osteoblasts
under the influence of growth factors highly concentrated in the
bone matrix, such as BMPs and IGFs, and ultimately contribute to
the new bone formation associated with intermittent PTH
injections.
Normal adult bone does not have modeling-based bone
formation. However, bone formation with PTH appears to result
from an increase in the rate of both remodeling and modeling
(reviewed in [39,40]). The mechanism proposed above could
contribute to both types of bone formation. A recent finding from
Wu et al. suggests a similar effect of PTH on mesenchymal
progenitor migration but through a distinct mechanism [18]. They
observed an increase in the migration of Sca-1-positive skeletal
stem cells toward the bone surface after 1 week of PTH injections,
which is dependent on PTH-induced bone resorption and
Figure 5. EGFR signaling mediates the chemotactic effect of PTH on mesenchymal progenitors. (A) Conditioned media from PTH-treated
UMR 106-01 cells increased the phosphorylation of EGFR in mesenchymal progenitors. In this experiment, mesenchymal progenitors were treated
with conditioned media for 5 min and then lysed for Western blot. (B) The enhanced phosphorylation of Akt and p38MAPK in mesenchymal
progenitors by conditioned media from PTH-treated UMR106-01 cells is dependent on the EGFR pathway. Mesenchymal progenitors were pre-
incubated with either DMSO or gefitinib (10 mM, GEF) for 30 min followed by addition of conditioned media to the culture. Cell lysates were collected
5 min later for Western blot analyses. (C) The EGFR inhibitor PD153035 (10 mM, PD) was added to both the upper and lower wells of the chemotaxis
assay and partially blocked the PTH-induced chemotactic activity of conditioned media from UMR 106-01 cells. ***: p,0.001 vs. DMSO CON; &:
p,0.01 vs. DMSO PTH. (D) An EGFR neutralizing antibody (4 mg/ml) was mixed with mesenchymal progenitors before the chemotaxis assay and
suppressed the migration of mesenchymal progenitors towards conditioned media from PTH-treated UMR 106-01 cells. IgG: isotype control. **:
p,0.01; ***: p,0.001 vs. CON; $: p,0.05; #:p ,0.001 vs. PTH. (E) qRT-PCR demonstrates the knockdown of EGFR mRNA levels in mesenchymal
progenitors by siRNAs. ***: p,0.001 vs. MOCK. (F) Immunoblotting reveals that the EGFR protein level was dramatically decreased in mesenchymal
progenitors transfected with siRNAs for EGFR. (G) Blocking of EGFR expression in mesenchymal progenitors by siRNAs abolished the chemotactic
migration of these cells toward conditioned media from PTH-treated UMR 106-01 cells. ***: p,0.001 vs. mock CON; #:p ,0.001 vs. mock PTH.
doi:10.1371/journal.pone.0050099.g005
PTH Stimulates the Migration of Bone Progenitors
PLOS ONE | www.plosone.org 8 December 2012 | Volume 7 | Issue 12 | e50099subsequent TGFb1 release from the bone matrix. Since our data
show that PTH directly stimulates chemotactic factor secretion
from osteoblasts and osteocytes, it would be interesting to examine
whether amphiregulin and TGFb1 are synergistic in recruiting
mesenchymal progenitors toward bone surfaces. In addition, the
notion that PTH stimulates the migration of mesenchymal
progenitors toward the bone surface is also consistent with a
new finding that PTH treatment relocates the small blood vessels
in the bone marrow, which harbors the niche for MSCs, closer to
the bone forming surface [41].
Previous reports and our data demonstrate that osteoblasts and
osteocytes are the major target of PTH. In bone, PTH1R
primarily exists in osteoblasts, osteocytes, and chondrocytes but
not in osteoclasts [3,4]. In situ hybridization revealed that the most
intense areas for PTH1R transcript expression were a specific
maturation stage of the growth plate, mature osteoblasts lining
trabecular bones, and cortical periosteal and endosteal surfaces
[4,42]. More importantly, the expression of the PTH early-
response gene c-fos is first strongly elevated in trabecular,
periosteal and endosteal osteoblasts and chondrocytes within 15–
30 min after one PTH injection and then followed by stromal cells
and osteoclasts after 1–2 hr [42]. Our qRT-PCR data analyzing
the expression of PTH1R in three different differentiation stages of
rat calvarial primary osteoblastic cultures further demonstrate that
the highest PTH1R expression occurs at the late osteoblast
mineralization stage (Fig. 2B). This is also consistent with our
previous observation that PTH-regulated genes, such as amphir-
egulin, usually exhibit much higher PTH-responsiveness in
differentiated osteoblasts than in preosteoblasts [21]. The expres-
sion of PTH1R in osteocytes was first suggested by in situ
hybridization [4] and its important role in regulating bone
structures was later confirmed by either osteocyte-specific deletion
[43] or targeted overexpression mouse models [44]. In addition,
PTH-induced suppression of sclerostin in osteocytes is considered
as one of the mechanisms by which PTH stimulates bone
formation [45]. On the contrary, mesenchymal progenitors do
express PTH1R but the level of PTH1R is so low that there was
no detectable change of cAMP production in these cells after PTH
Figure 6. PTH stimulates the release of amphiregulin from osteoblasts to promote mesenchymal progenitor migration. (A) EGF-like
ligands are chemotactic factors for mesenchymal progenitors. aMEM containing various amounts of EGF-like ligands was added in the lower wells of
chemotaxis assays using rat mesenchymal progenitors. aMEM containing 5% FBS was used as positive control. *: p,0.05; **: p,0.01; ***: p,0.001 vs.
CON. (B) Addition of GM6001 (10 mM, GM) in the chemotaxis assay blocked the migration of mesenchymal progenitors toward conditioned media
from PTH-treated UMR 106-01 cells. ***: p,0.001 vs. CON DMSO; #:p ,0.001 vs. PTH DMSO. (C) qRT-PCR shows that PTH (10 nM) induced the
expression of amphiregulin in osteocytic Ocy491 cells at 1 h. (D) qRT-PCR demonstrates the knockdown of amphiregulin mRNA in UMR 106-01 cells
after 1 hr of PTH (10 nM) treatment by siRNAs. **: p,0.01 vs. mock1. (E) Chemotaxis assays reveal that PTH did not stimulate the release of
chemotactic factor(s) from UMR106-01 cells transfected with siRNAs for amphiregulin. ***: p,0.001 vs. CON CM; #;p ,0.001 vs PTH CM mock1. (F)
Amphiregulin (AR) stimulated Akt and p38MAPK phosphorylation in mesenchymal progenitors as shown by immunoblotting.
doi:10.1371/journal.pone.0050099.g006
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possibility that PTH regulates mesenchymal progenitors directly
in a migration-independent manner. It should be pointed out that
untreated osteoblastic and osteocytic cells also secrete chemotactic
factors for mesenchymal progenitors (Fig. 1B, comparing control
and aMEM), suggesting that osteoblasts and osteocytes may play
an important role in progenitor migration for normal bone
remodeling independent of PTH treatment.
Our data strongly suggest that activation of EGFR by EGF-like
ligands, especially amphiregulin, is vital for the migratory response
of mesenchymal progenitors to PTH. Amphiregulin is one of the
most upregulated genes after PTH treatment of osteoblasts. EGF
and HB-EGF have been studied as exogenous growth factors for
ex vivo expansion of the mesenchymal progenitor population
[30,31]. We previously have demonstrated that the EGFR
signaling pathway is important for mesenchymal progenitor
maintenance [24]. Here, we demonstrate that, unlike the majority
of the cells that compose the bone marrow, the hematopoietic
cells, mesenchymal progenitors express EGFR and are the main
targets of EGF-like ligands in the bone marrow. We found that all
EGF-like ligands are potent chemoattractants for mesenchymal
progenitors in vitro. EGF-like ligands are also known chemoat-
tractants for other cells such as intestinal epithelial cells [46] and
breast cancer cells [47,48]. Loss of EGFR activity using an
Figure 7. The anabolic actions of PTH on trabecular bone are attenuated in EGFR-deficient mice. (A) pQCT measurement of total and
trabecular BMDs of the proximal tibiae of vehicle- or PTH-injected Col-Cre Egfr
Wa5/flox mice, their Wa5 (Egfr
Wa5/flox) and wild type (WT) siblings. (B)
Structural parameters of trabecular bone in the proximal tibiae of vehicle- or PTH-injected Col-Cre Egfr
Wa5/flox and WT mice. BV/TV: trabecular bone
volume/tissue volume; TbTh: trabecular thickness; TbSp: trabecular separation; TbN: trabecular number; TbPf: trabecular pattern factor; SMI: structure
model index. (C) Bone histomorphometry revealed that PTH-induced osteoblast formation is blunted in Col-Cre Egfr
Wa5/flox mice. *: p,0.05; **:
p,0.01; ***: p,0.001 PTH vs. veh; &: p,0.05; #:p ,0.01 vehicle-treated Col-Cre Egfr
Wa5/flox vs vehicle-treated WT mice. n=5–7 mice per group.
doi:10.1371/journal.pone.0050099.g007
Figure 8. A model for PTH-induced mesenchymal progenitor
migration in bone.
doi:10.1371/journal.pone.0050099.g008
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icantly decreased the migration of mesenchymal progenitors
toward PTH-treated conditioned media, providing direct evidence
that activation of EGFR is involved in PTH-induced mesenchymal
progenitor migration. Conditioned media from PTH-treated
osteoblasts also stimulated the phosphorylation of EGFR, dem-
onstrating that the EGFR was activated by a factor(s) released by
osteoblasts. Furthermore, knockdown of amphiregulin expression
in osteoblasts abolished the increased migration of mesenchymal
progenitors toward the PTH-treated conditioned media, suggest-
ing that amphiregulin is critical for the migratory effect of PTH.
However, knockdown of amphiregulin did not significantly affect
the migration toward control conditioned media, suggesting that
amphiregulin expression in the absence of PTH treatment may be
too low to mediate osteoblast-simulated mesenchymal progenitor
migration. Loss of PI3K/Akt and p38MAPK activity, two
downstream signaling pathways of the EGFR, also inhibited
migration toward PTH-treated conditioned media. These path-
ways have been previously shown to play a role in EGF-stimulated
motility of intestinal epithelial cells [49,50]. We therefore propose
that PTH stimulates mesenchymal progenitor migration indirectly
through activation of the EGFR on mesenchymal progenitors and
subsequent activation of the PI3K and p38MAPK signaling
pathways.
Our data also suggest that EGFR activity in osteoprogenitors is
required for a full anabolic response to PTH. We previously
demonstrated that loss of EGFR in osteoprogenitors/osteoblasts
(Col-Cre Egfr
Wa5/flox mice) led to a significant decrease in EGFR
activity in osteoprogenitors, great reduction in bone mass, and
suppression of bone formation in skeletally mature mice [24].
Here, we demonstrate that these mice do not respond to PTH with
an anabolic response in bone. A recent study reported normal
anabolic actions of PTH on Egfr
Wa5/+ mice [38], which is
consistent with our current findings. Although Egfr
Wa5/+ mice
have low EGFR activity, we and other groups found that they
exhibit similar bone phenotypes as wild-type mice [24,37,38]. We
had to combine conditional Egfr knockout with the Wa5 mutation
to achieve a more complete reduction in EGFR activity in order to
observe significant bone phenotypes [24]. Therefore, we believe
that the Wa5 mice still exhibit a significant bone anabolic response
to PTH since they only have a moderate reduction in EGFR
activity and a larger reduction in EGFR activity, such as what we
have achieved with Col-Cre Egfr
Wa5/flox mice, is required to
demonstrate the effect of loss of EGFR activity on PTH treatment.
In summary, our data indicate that PTH stimulates osteoblasts
and osteocytes to release amphiregulin which acts as a soluble
chemotactic factor for mesenchymal progenitors. Together with
our previous reports that activation of EGFR signaling stimulates
the proliferation of mesenchymal progenitors but inhibits their
differentiation, and our in vivo finding that the skeleton of EGFR-
deficient mice does not respond to PTH injections, we propose
that EGFR signaling plays an important role in mediating the
anabolic response of bone to PTH treatment and therefore, it
represents a new target for anabolic osteoporosis therapy.
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